Now showing items 1-5 of 5

    • Assessing HER2 Amplification in Plasma cfDNA. 

      Garcia-Murillas, I; Turner, NC (2018-01)
      Digital PCR (dPCR) is a highly accurate method to determine DNA concentration. In dPCR, DNA is portioned into many discrete single entities, and these are analyzed individually for the presence or absence of a target ...
    • Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. 

      Natrajan, R; Wilkerson, PM; Marchiò, C; Piscuoglio, S; Ng, CKY; Wai, P; Lambros, MB; Samartzis, EP; Dedes, KJ; Frankum, J; Bajrami, I; Kopec, A; Mackay, A; A'hern, R; Fenwick, K; Kozarewa, I; Hakas, J; Mitsopoulos, C; Hardisson, D; Lord, CJ; Kumar-Sinha, C; Ashworth, A; Weigelt, B; Sapino, A; Chinnaiyan, AM; Maher, CA; Reis-Filho, JS (2014-04)
      Micropapillary carcinoma (MPC) is a rare histological special type of breast cancer, characterized by an aggressive clinical behaviour and a pattern of copy number aberrations (CNAs) distinct from that of grade- and oestrogen ...
    • Identifying Genetic Dependencies in Cancer by Analyzing siRNA Screens in Tumor Cell Line Panels. 

      Campbell, J; Ryan, CJ; Lord, CJ (2018-01)
      Loss-of-function screening using RNA interference or CRISPR approaches can be used to identify genes that specific tumor cell lines depend upon for survival. By integrating the results from screens in multiple cell lines ...
    • Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. 

      Ng, CKY; Martelotto, LG; Gauthier, A; Wen, H-C; Piscuoglio, S; Lim, RS; Cowell, CF; Wilkerson, PM; Wai, P; Rodrigues, DN; Arnould, L; Geyer, FC; Bromberg, SE; Lacroix-Triki, M; Penault-Llorca, F; Giard, S; Sastre-Garau, X; Natrajan, R; Norton, L; Cottu, PH; Weigelt, B; Vincent-Salomon, A; Reis-Filho, JS (2015-05-22)
      <h4>Background</h4>HER2 is overexpressed and amplified in approximately 15% of invasive breast cancers, and is the molecular target and predictive marker of response to anti-HER2 agents. In a subset of these cases, ...
    • Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours. 

      Litchfield, K; Summersgill, B; Yost, S; Sultana, R; Labreche, K; Dudakia, D; Renwick, A; Seal, S; Al-Saadi, R; Broderick, P; Turner, NC; Houlston, RS; Huddart, R; Shipley, J; Turnbull, C (2015-01-22)
      Testicular germ cell tumours (TGCTs) are the most common cancer in young men. Here we perform whole-exome sequencing (WES) of 42 TGCTs to comprehensively study the cancer's mutational profile. The mutation rate is uniformly ...